FMP
Aadi Bioscience, Inc.
AADI
NASDAQ
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
1.68 USD
-0.1 (-5.95%)
About
ceo
Mr. David J. Lennon Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://aadibio.com
exchange
NASDAQ
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
CIK
0001422142
ISIN
US00032Q1040
CUSIP
00032Q104
Address
17383 Sunset Boulevard
Phone
424 473 8055
Country
US
Employee
89
IPO Date
Feb 16, 2018
Key Executives
